NASDAQ:JNCE Jounce Therapeutics - JNCE Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Jounce Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $1.13 -0.06 (-5.04%) (As of 01/30/2023 12:00 AM ET) Add Compare Share Share Today's Range$1.12▼$1.2250-Day Range$0.64▼$1.2952-Week Range$0.58▼$8.80Volume262,512 shsAverage Volume963,137 shsMarket Capitalization$58.41 millionP/E RatioN/ADividend YieldN/APrice Target$8.20 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Jounce Therapeutics MarketRank™ ForecastAnalyst RatingModerate Buy2.83 Rating ScoreUpside/Downside625.7% Upside$8.20 Price TargetShort InterestHealthy3.97% of Float Sold ShortDividend StrengthN/ASustainability-0.67Upright™ Environmental ScoreNews Sentiment1.15Based on 5 Articles This WeekInsider TradingSelling Shares$41,929 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($1.98) to ($2.25) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.66 out of 5 starsMedical Sector92nd out of 1,055 stocksBiological Products, Except Diagnostic Industry15th out of 170 stocks 3.4 Analyst's Opinion Consensus RatingJounce Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $8.20, Jounce Therapeutics has a forecasted upside of 625.7% from its current price of $1.13.Amount of Analyst CoverageJounce Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted3.97% of the float of Jounce Therapeutics has been sold short.Short Interest Ratio / Days to CoverJounce Therapeutics has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Jounce Therapeutics has recently decreased by 46.26%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldJounce Therapeutics does not currently pay a dividend.Dividend GrowthJounce Therapeutics does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreJounce Therapeutics has received a 75.46% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Preclinical research services for physical health" and "Clinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Jounce Therapeutics is -0.67. Previous Next 2.9 News and Social Media Coverage News SentimentJounce Therapeutics has a news sentiment score of 1.15. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.72 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Jounce Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 6 people have searched for JNCE on MarketBeat in the last 30 days. This is a decrease of -65% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Jounce Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $41,929.00 in company stock.Percentage Held by InsidersOnly 6.92% of the stock of Jounce Therapeutics is held by insiders.Percentage Held by Institutions80.66% of the stock of Jounce Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Jounce Therapeutics are expected to decrease in the coming year, from ($1.98) to ($2.25) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Jounce Therapeutics is -0.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Jounce Therapeutics is -0.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioJounce Therapeutics has a P/B Ratio of 0.26. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Jounce Therapeutics (NASDAQ:JNCE) StockJounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid tumors. It is also developing JTX-8064, an antibody that binds to leukocyte immunoglobulin like receptor B2, which is a cell surface receptor expressed on macrophages; JTX -1484 for myeloid; and JTX-1811, an anti-CCR8 monoclonal antibody designed to selectively deplete intra-tumoral T regulatory cells in the tumor microenvironment. Jounce Therapeutics, Inc. was incorporated in 2012 and is headquartered in Cambridge, Massachusetts.Read More Receive JNCE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Jounce Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address JNCE Stock News HeadlinesJanuary 27, 2023 | americanbankingnews.comJounce Therapeutics, Inc. (NASDAQ:JNCE) Short Interest Down 46.3% in JanuaryJanuary 25, 2023 | nasdaq.comCowen Financial Products LLC Ups Stake in Jounce Therapeutics Inc (JNCE)January 31, 2023 | Porter & Company (Ad)Is This The End of Capitalism?EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…January 12, 2023 | reuters.comJNCE.O - | Stock Price & Latest News | ReutersJanuary 4, 2023 | finance.yahoo.comGilead's (GILD) Application for Trodelvy Gets EMA ValidationDecember 28, 2022 | finance.yahoo.comGilead Sciences Acquires Jounce Therapeutics Cancer Immunotherapy ProgramDecember 28, 2022 | finance.yahoo.comGilead (GILD) To Get Full Rights for Jounce's ImmunotherapyDecember 28, 2022 | finanznachrichten.deJounce Therapeutics, Inc.: Gilead To Acquire All Remaining Rights To Potential First-In-Class Immunotherapy GS-1811 From Jounce TherapeuticsJanuary 31, 2023 | Porter & Company (Ad)Is This The End of Capitalism?EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…December 25, 2022 | forbes.comJounce TherapeuticsDecember 20, 2022 | finance.yahoo.comWe're A Little Worried About Jounce Therapeutics' (NASDAQ:JNCE) Cash Burn RateDecember 8, 2022 | tmcnet.comJounce Therapeutics Presents INNATE Phase 1 and SELECTDecember 8, 2022 | finance.yahoo.comJounce Therapeutics Presents INNATE Phase 1 and SELECT Clinical Trial data at the European Society of Medical Oncology Immuno-Oncology (ESMO - IO) Annual CongressNovember 10, 2022 | seekingalpha.comJounce Therapeutics, Inc. (JNCE) Q3 2022 Results - Earnings Call TranscriptNovember 10, 2022 | finance.yahoo.comJounce Therapeutics Reports Third Quarter 2022 Financial ResultsNovember 2, 2022 | finance.yahoo.comJounce Therapeutics earns clinical milestone payment under the CCR8 exclusive license agreement with Gilead Sciences, Inc.October 27, 2022 | finance.yahoo.comJounce Therapeutics to Announce Third Quarter 2022 Financial Results and Host Conference Call on Thursday, November 10, 2022October 20, 2022 | finance.yahoo.comJounce Therapeutics to Present Multiple Posters at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting and the European Society of Medical Oncology Immuno-Oncology (ESMO-IO) Annual CongressOctober 17, 2022 | nasdaq.comIs Jounce Therapeutics (NASDAQ:JNCE) In A Good Position To Deliver On Growth Plans?September 7, 2022 | finance.yahoo.comJounce Therapeutics to Participate in the Upcoming Investor ConferencesAugust 31, 2022 | nasdaq.comJounce (JNCE) SELECT Study Fails to Meet Goal, Stock DownAugust 30, 2022 | finance.yahoo.comJounce Therapeutics Shares Fall After Disappointing Mid-Stage Lung Cancer Trial DataAugust 30, 2022 | marketwatch.comJounce Therapeutics Trial Fails to Meet Primary EndpointAugust 30, 2022 | markets.businessinsider.comJounce Therapeutics: SELECT Trial Of Vopratelimab Fails To Meet Primary EndpointAugust 30, 2022 | seekingalpha.comJounce drops ~29% as lung cancer therapy fails in mid-stage trialAugust 30, 2022 | finance.yahoo.comJounce Therapeutics Reports Results from Phase 2 Randomized SELECT Trial Testing 2 Different Doses of Vopratelimab in TISvopra Biomarker-Selected PatientsAugust 5, 2022 | seekingalpha.comJounce Therapeutics, Inc. (JNCE) CEO Richard Murray on Q2 2022 Results - Earnings Call TranscriptSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive JNCE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Jounce Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address JNCE Company Calendar Last Earnings11/10/2022Today1/30/2023Next Earnings (Estimated)3/01/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:JNCE CUSIPN/A CIK1640455 Webwww.jouncetx.com Phone(857) 259-3840FaxN/AEmployees137Year FoundedN/APrice Target and Rating Average Stock Price Forecast$8.20 High Stock Price Forecast$17.00 Low Stock Price Forecast$3.00 Forecasted Upside/Downside+625.7%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($2.56) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-90,870,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-75.51% Return on Assets-64.89% Debt Debt-to-Equity RatioN/A Current Ratio6.42 Quick Ratio6.42 Sales & Book Value Annual Sales$26.91 million Price / Sales2.17 Cash FlowN/A Price / Cash FlowN/A Book Value$4.37 per share Price / Book0.26Miscellaneous Outstanding Shares51,694,000Free Float48,117,000Market Cap$58.41 million OptionableOptionable Beta0.88 Key ExecutivesDr. Richard Murray Ph.D. (Age 64)Pres, CEO & Director Comp: $887.4kMr. Hugh M. Cole (Age 58)Chief Operating Officer Comp: $607.44kDr. Elizabeth G. Trehu M.D. (Age 63)Chief Medical Officer Comp: $639.6kDr. James Patrick Allison Ph.D.FounderDr. Thomas F. Gajewski M.D.Ph.D., FounderDr. Robert D. Schreiber Ph.D.FounderDr. Drew Mark Pardoll M.D.Ph.D., FounderDr. Padmanee Sharma M.D.Ph.D., FounderDr. Louis M. Weiner M.D. (Age 71)Founder Ms. Kimberlee Cobleigh Drapkin CPA (Age 55)CPA, CFO & Treasurer More ExecutivesKey CompetitorsEiger BioPharmaceuticalsNASDAQ:EIGRCognition TherapeuticsNASDAQ:CGTXSurface OncologyNASDAQ:SURFMiromatrix MedicalNASDAQ:MIROSolid BiosciencesNASDAQ:SLDBView All CompetitorsInsiders & InstitutionsMoloney Securities Asset Management LLCBought 355,119 shares on 1/30/2023Ownership: 0.933%Assenagon Asset Management S.A.Sold 277,713 shares on 1/12/2023Ownership: 1.011%Richard /Ca/ MurraySold 20,191 sharesTotal: $22,210.10 ($1.10/share)Hugh M ColeSold 7,452 sharesTotal: $8,197.20 ($1.10/share)Elizabeth TrehuSold 4,159 sharesTotal: $4,574.90 ($1.10/share)View All Insider TransactionsView All Institutional Transactions JNCE Stock - Frequently Asked Questions Should I buy or sell Jounce Therapeutics stock right now? 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Jounce Therapeutics in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" JNCE shares. View JNCE analyst ratings or view top-rated stocks. What is Jounce Therapeutics' stock price forecast for 2023? 6 equities research analysts have issued 1-year price targets for Jounce Therapeutics' stock. Their JNCE share price forecasts range from $3.00 to $17.00. On average, they anticipate the company's stock price to reach $8.20 in the next year. This suggests a possible upside of 625.7% from the stock's current price. View analysts price targets for JNCE or view top-rated stocks among Wall Street analysts. How have JNCE shares performed in 2023? Jounce Therapeutics' stock was trading at $1.11 at the beginning of 2023. Since then, JNCE stock has increased by 1.8% and is now trading at $1.13. View the best growth stocks for 2023 here. Are investors shorting Jounce Therapeutics? Jounce Therapeutics saw a drop in short interest in the month of January. As of January 15th, there was short interest totaling 1,580,000 shares, a drop of 46.3% from the December 31st total of 2,940,000 shares. Based on an average trading volume of 1,550,000 shares, the short-interest ratio is presently 1.0 days. Approximately 4.0% of the company's shares are short sold. View Jounce Therapeutics' Short Interest. When is Jounce Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 1st 2023. View our JNCE earnings forecast. How were Jounce Therapeutics' earnings last quarter? Jounce Therapeutics, Inc. (NASDAQ:JNCE) issued its quarterly earnings data on Thursday, November, 10th. The company reported ($0.60) EPS for the quarter, beating analysts' consensus estimates of ($0.64) by $0.04. What is Richard Murray Ph.D's approval rating as Jounce Therapeutics' CEO? 45 employees have rated Jounce Therapeutics Chief Executive Officer Richard Murray Ph.D on Glassdoor.com. Richard Murray Ph.D has an approval rating of 97% among the company's employees. This puts Richard Murray Ph.D in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Jounce Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Jounce Therapeutics investors own include Exelixis (EXEL), Teva Pharmaceutical Industries (TEVA), Bausch Health Companies (BHC), CRISPR Therapeutics (CRSP), Novavax (NVAX), Mylan (MYL), Progenics Pharmaceuticals (PGNX), Adaptimmune Therapeutics (ADAP), Incyte (INCY) and Nektar Therapeutics (NKTR). When did Jounce Therapeutics IPO? (JNCE) raised $76 million in an IPO on Friday, January 27th 2017. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan and Cowen and Company served as the underwriters for the IPO and Wells Fargo Securities and Baird were co-managers. What is Jounce Therapeutics' stock symbol? Jounce Therapeutics trades on the NASDAQ under the ticker symbol "JNCE." Who are Jounce Therapeutics' major shareholders? Jounce Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Assenagon Asset Management S.A. (1.01%), Moloney Securities Asset Management LLC (0.93%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Barbara Gayle Duncan, Elizabeth Trehu, Hugh M Cole, John Duncan Higgons, Kimberlee C Drapkin, Richard /Ca/ Murray, Rock Ventures Ii LP Third and Rock Ventures Iii LP Third. View institutional ownership trends. How do I buy shares of Jounce Therapeutics? Shares of JNCE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Jounce Therapeutics' stock price today? One share of JNCE stock can currently be purchased for approximately $1.13. How much money does Jounce Therapeutics make? Jounce Therapeutics (NASDAQ:JNCE) has a market capitalization of $58.41 million and generates $26.91 million in revenue each year. The company earns $-90,870,000.00 in net income (profit) each year or ($2.56) on an earnings per share basis. How many employees does Jounce Therapeutics have? The company employs 137 workers across the globe. How can I contact Jounce Therapeutics? Jounce Therapeutics' mailing address is 780 MEMORIAL DRIVE, CAMBRIDGE MA, 02139. The official website for the company is www.jouncetx.com. The company can be reached via phone at (857) 259-3840 or via email at mdeon@jouncetx.com. This page (NASDAQ:JNCE) was last updated on 1/31/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.